SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.97), in-line with the analyst estimate of ($1.97).

Cash Position: Cash, cash equivalents, and marketable securities as of September 30, 2017 were $243.5 million, compared with $397.5 million at December 31, 2016.

“We are on the verge of important data readouts as we move into the last quarter of 2017, and as we continue to make progress in executing on our R&D strategy,” said Jeff Jonas, M.D., Chief Executive Officer of Sage. “Sage has focused on understanding the underlying mechanisms of CNS disorders and developing novel treatments that may address current treatment gaps. We are pleased that our open-label data in Parkinson’s disease and essential tremor demonstrate potential for further development. The upcoming months have the potential to be transformational for Sage as we seek to bring new treatments to patients impacted by life-altering CNS disorders.”

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.